In 2019, we examined cell-based therapies through both scientific and commercial lenses. Over the last year, the field has dramatically advanced beyond the recently approved CD-19 CAR-T therapies (KYMRIAH and YESCARTA) into novel cell types and designs with potential across tumor types. In this first part of a two-part series, we will review recent and anticipated near-term clinical, regulatory, and commercial updates.
